clofibrate has been researched along with Hyperlipoproteinemia Type III in 17 studies
angiokapsul: contains clofibrate & insoitolnicotinate
Hyperlipoproteinemia Type III: An autosomal recessively inherited disorder characterized by the accumulation of intermediate-density lipoprotein (IDL or broad-beta-lipoprotein). IDL has a CHOLESTEROL to TRIGLYCERIDES ratio greater than that of VERY-LOW-DENSITY LIPOPROTEINS. This disorder is due to mutation of APOLIPOPROTEINS E, a receptor-binding component of VLDL and CHYLOMICRONS, resulting in their reduced clearance and high plasma levels of both cholesterol and triglycerides.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ten patients with type III and 10 with type IV hyperlipoproteinemia participated in a comparative open cross-over study of the effect of acipimox (750 mg/day) and clofibrate (2 g/day) on lipoproteins, apoliproproteins and postheparin lipase activities during 6 weeks." | 2.66 | A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia. ( Demacker, PN; Stalenhoef, AF; Stuyt, PM; Van 't Laar, A, 1985) |
| "Treatment with clofibrate and gemfibrozil both resulted in significant reductions in the plasma concentrations of total cholesterol (40% and 54%), VLDL cholesterol (59% and 79%) and total triglycerides (48% and 70%), as well as a significant increase in HDL cholesterol (9% and 7%)." | 1.29 | Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia. ( Illingworth, DR; Larsen, ML; O'Malley, JP, 1994) |
| "Most patients with type III hyperlipoproteinemia have a structural defect in apolipoprotein E associated with increased synthesis and decreased catabolism of apolipoprotein E, delayed catabolism of chylomicron remnants, and development of plasma lipoprotein abnormalities characteristic of type III hyperlipoproteinemia." | 1.27 | NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. ( Brewer, HB; Gregg, RE; Schaefer, EJ; Schwartz, D; Zech, LA, 1983) |
| " All patients were dietary adapted before the preliminary wash-out period of 4 weeks and received etofylline clofibrate in a dosage of 500 mg/day (2x1 capsule) over 4 weeks, and 750 mg/day (3 x 1 capsule) over further 4 months." | 1.26 | [Clinical effects and tolerance of etofylline clofibrate]. ( Metz, G; Specker, M; Ziegler, WJ, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (82.35) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keen, H | 1 |
| Lewis, B | 2 |
| Miller, NE | 1 |
| Wynn, V | 1 |
| Hazzard, WR | 1 |
| Miller, N | 1 |
| Albers, JJ | 1 |
| Warnick, GR | 1 |
| Baron, P | 1 |
| Kaffarnik, H | 1 |
| Schneider, J | 1 |
| Schubotz, R | 1 |
| Zöfel, P | 1 |
| Hausmann, L | 1 |
| Goebel, KM | 1 |
| Brewer, HB | 1 |
| Zech, LA | 1 |
| Gregg, RE | 1 |
| Schwartz, D | 1 |
| Schaefer, EJ | 1 |
| Stuyt, PM | 2 |
| Demacker, PN | 2 |
| Stalenhoef, AF | 2 |
| Schade, RW | 1 |
| Lutterman, JA | 1 |
| van't Laar, A | 1 |
| Naruszewicz, M | 1 |
| Nowicka, G | 1 |
| Szostak, WB | 1 |
| Kłosiewicz-Latoszek, L | 1 |
| Ziegler, WJ | 1 |
| Metz, G | 1 |
| Specker, M | 1 |
| Faergeman, O | 1 |
| Meinertz, H | 1 |
| Larsen, ML | 1 |
| Illingworth, DR | 2 |
| O'Malley, JP | 2 |
| Sullivan, PM | 1 |
| Mezdour, H | 1 |
| Quarfordt, SH | 1 |
| Maeda, N | 1 |
| Gotto, AM | 1 |
| Jones, PH | 1 |
| Scott, LW | 1 |
| Brown, WV | 1 |
| Janus, ED | 1 |
| Grant, S | 1 |
| Lintott, CJ | 1 |
| Wardell, MR | 1 |
| Van 't Laar, A | 1 |
| Parker, F | 1 |
| Hoogwerf, BJ | 1 |
| Peters, JR | 1 |
| Frantz, ID | 1 |
| Hunninghake, DB | 1 |
1 review available for clofibrate and Hyperlipoproteinemia Type III
| Article | Year |
|---|---|
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibr | 1986 |
2 trials available for clofibrate and Hyperlipoproteinemia Type III
| Article | Year |
|---|---|
The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia.
Topics: Adult; Aged; Cholesterol; Clinical Trials as Topic; Clofibrate; Drug Therapy, Combination; Female; F | 1990 |
A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins A; Apolipoproteins B; Choleste | 1985 |
14 other studies available for clofibrate and Hyperlipoproteinemia Type III
| Article | Year |
|---|---|
Clofibrate and hyperlipidaemia.
Topics: Clofibrate; Diabetic Retinopathy; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Ty | 1980 |
Association of isoapolipoprotein-E3 deficiency with heterozygous familial hypercholesterolaemia: implications for lipoprotein physiology.
Topics: Apolipoprotein E3; Apolipoproteins; Apolipoproteins E; Child; Clofibrate; Female; Heterozygote; Huma | 1981 |
Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Creatine Kinase; Female; gamma-Glutamyltransfe | 1980 |
NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment.
Topics: Adolescent; Adult; Aged; Apolipoproteins; Clofibrate; Coronary Vessels; Diet; Female; Humans; Hyperl | 1983 |
Type III hyperlipoproteinaemia: the turnover rate of plasma triglycerides and the response to clofibrate.
Topics: Adult; Aged; Cholesterol; Clofibrate; Female; Humans; Hyperlipoproteinemia Type III; Lipoproteins; M | 1982 |
[Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; | 1982 |
[Clinical effects and tolerance of etofylline clofibrate].
Topics: Clofibrate; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hy | 1980 |
[Type III hyperlipoproteinemia. A review and clinical and biochemical findings in 11 patients].
Topics: Adult; Aged; Clofibrate; Female; Humans; Hyperlipoproteinemia Type III; Male; Middle Aged | 1980 |
Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia.
Topics: Adult; Aged; Cholesterol; Clofibrate; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type III; Li | 1994 |
Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Cholesterol; Clofibrate; Dietary Fats; Female; Gene Ta | 1998 |
Potential use of fenofibrate and other fibric acid derivatives in the clinic.
Topics: Clofibrate; Fenofibrate; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hy | 1987 |
Apolipoprotein E phenotypes in hyperlipidaemic patients and their implications for treatment.
Topics: Adult; Aged; Apolipoproteins E; Cholesterol; Cholesterol, VLDL; Clofibrate; Diseases in Twins; Femal | 1985 |
Xanthomas and hyperlipidemias.
Topics: Apoproteins; Arteriosclerosis; Cholestasis; Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyr | 1985 |
Effect of clofibrate and colestipol singly and in combination on plasma lipids and lipoproteins in type III hyperlipoproteinemia.
Topics: Adult; Body Weight; Cholesterol; Clofibrate; Colestipol; Drug Therapy, Combination; Humans; Hyperlip | 1985 |